Organon (OGN) Inventory Average (2021 - 2026)
Organon (OGN) posted quarterly Inventory Average of $1.4 billion for Q1 2026, up 3.58% year-over-year from $1.3 billion in Q1 2025, and down 3.97% on a QoQ basis from $1.4 billion in Q4 2025.
Organon (OGN) Inventory Average (2021 - 2026) Analysis & Trends
Organon (OGN) has reported Inventory Average for 6 consecutive years, with $1.4 billion the latest figure, recorded in Q1 2026.
- In Q1 2026, Inventory Average rose 3.58% year-over-year to $1.4 billion; the TTM figure through Mar 2026 stood at $1.4 billion (up 3.58% YoY), while the FY2025 annual figure was $1.4 billion, up 3.45% from the prior year.
- Inventory Average came in at $1.4 billion for Q1 2026 at Organon, down from $1.4 billion in the prior quarter.
- The five-year high for Inventory Average was $1.5 billion in Q3 2025, with the low at $914.5 million in Q3 2022.
- Average Inventory Average over 5 years is $1.2 billion, with a median of $1.3 billion recorded in 2024.
- Across the five-year window, Inventory Average grew 1.31% in 2022 and soared 32.89% in 2023, its largest moves.
- Year by year, Inventory Average stood at $941.0 million in 2022, then jumped by 32.89% to $1.3 billion in 2023, then gained by 8.12% to $1.4 billion in 2024, then increased by 7.03% to $1.4 billion in 2025, then dropped by 3.97% to $1.4 billion in 2026.
- According to Business Quant data, Inventory Average over the past three periods registered $1.4 billion, $1.4 billion, and $1.5 billion for Q1 2026, Q4 2025, and Q3 2025 respectively.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Inventory Avg. (Qtr) |
|---|---|---|---|---|---|
| 1 | Eli Lilly | 1,066.16 Bn | 1,060.88 Bn | 16.22 Bn | 14.14 Bn |
| 2 | Johnson & Johnson | 611.69 Bn | 589.64 Bn | 15.96 Bn | 14.39 Bn |
| 3 | AbbVie | 444.34 Bn | 434.99 Bn | 10.78 Bn | 5.00 Bn |
| 4 | Astrazeneca | 284.94 Bn | 277.05 Bn | 12.61 Bn | 6.56 Bn |
| 5 | Merck | 224.23 Bn | 218.58 Bn | 12.09 Bn | 6.57 Bn |
| 6 | Amgen | 195.12 Bn | 183.08 Bn | 5.87 Bn | 6.21 Bn |
| 7 | Gilead Sciences | 156.45 Bn | 148.73 Bn | 5.52 Bn | 1.84 Bn |
| 8 | Pfizer | 136.01 Bn | 123.24 Bn | -1.21 Bn | 10.66 Bn |
| 9 | Novartis Ag | 113.45 Bn | 113.67 Bn | - | - |
| 10 | Organon | 3.53 Bn | 2.41 Bn | 783.00 Mn | 1.39 Bn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 1.39 Bn |
| Dec 31, 2025 | 1.45 Bn |
| Sep 30, 2025 | 1.47 Bn |
| Jun 30, 2025 | 1.41 Bn |
| Mar 31, 2025 | 1.34 Bn |
| Dec 31, 2024 | 1.35 Bn |
| Sep 30, 2024 | 1.34 Bn |
| Jun 30, 2024 | 1.28 Bn |
| Mar 31, 2024 | 1.29 Bn |
| Dec 31, 2023 | 1.25 Bn |
| Sep 30, 2023 | 1.19 Bn |
| Jun 30, 2023 | 1.16 Bn |
| Mar 31, 2023 | 1.06 Bn |
| Dec 31, 2022 | 941.00 Mn |
| Sep 30, 2022 | 914.50 Mn |
| Jun 30, 2022 | 948.00 Mn |
| Mar 31, 2022 | 930.50 Mn |
| Dec 31, 2021 | 916.50 Mn |
| Sep 30, 2021 | 894.50 Mn |
| Jun 30, 2021 | 897.50 Mn |